China’s National Medical Products Administration (NMPA) issued final implementation measures for drug trial data protection, a move aimed at better aligning China’s pharmaceutical IP framework with international standards. The rules mark a regulatory step toward formalizing how clinical data can be protected for subsequent approvals. For drug developers, the measure is likely to influence the economics and timing of lifecycle strategies around trial reuse and potential filings. It also signals a continued effort to strengthen predictability for innovators operating in China’s clinical development ecosystem. The update comes as sponsors face increasing complexity around data ownership, clinical package reuse, and market authorization timelines.